News Articles and Media
ALV003 Selected As One of Top 100 Great Investigational Drugs
Alvine Pharmaceuticals Inc. Emerging Company Profile, In Vivo/Start-Up Magazine, Windhover Information, Inc.
ALV003 Selected as One of Top 5 Most Promising Drugs Entering Phase 2 Clinical Trials by Thomson Reuters
The Ones to Watch, A Pharma Matters Report, Thomson Reuters, July-September 2009
ALV003 in Scientific American Article: Celiac Disease Insights: Clues to Solving Autoimmunity
ALV003 Highlighted in Datamonitor Research Report
Datamonitor Stakeholder Opinions: Celiac Disease Published April 2009